1 / 62

Thalidomide: From Safe Tranquilizer to Anticancer Drug and Its Impact on Limb Formation

Thalidomide, once a safe tranquilizer, revealed its dangerous effects during limb formation, leading to congenital disabilities such as reduced or absent arms and legs. The optical isomer of thalidomide inhibits blood vessel formation, which has spurred interest in its potential as an anticancer drug. Understanding its mechanism and the quaternary structure of associated proteins, such as thymidylate synthase, is crucial for further research. This exploration highlights the dual nature of thalidomide, illustrating both its therapeutic potential and teratogenic effects.

suzy
Télécharger la présentation

Thalidomide: From Safe Tranquilizer to Anticancer Drug and Its Impact on Limb Formation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Thalidomide effect – Fig. 3.29 1 optical isomer is a safe tranquilizer – mirror image inhibits blood vessel formation – use as anticancer drug?

  2. Thalidomide taken during narrow windows of limb formation gave reduced or no arms or legs – apparently by affecting blood vessel formation

  3. THE PEPTIDE BOND

  4. phageT4 thymidylate synthase. White: structure maintained; Red: universally conserved in bacteria and eukaryotes; yellow: unique to T4; purple: like archae

  5. QUATERNARY STRUCTURE

  6. Fig. 7.22

  7. Fig. 3.10

  8. Fig. 1.5

  9. Fig. 1.7

  10. Fig. 6.8

  11. Fig. 6.9c

  12. Fig. 6.9a

More Related